Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8514171 | Journal of Pharmaceutical Sciences | 2017 | 7 Pages |
Abstract
This study examined the safety, pharmacodynamic and pharmacokinetic similarity of the human recombinant filgrastim products ior®LeukoCIM and Neupogen® following a 28-day repeated subcutaneous dose administration in male and female Sprague-Dawley rats with a 14-day recovery period. Safety profiling was based on clinical observations, clinical pathology, and pathology findings for control rats dosed with vehicle and rats dosed either with 15, 75, and 150 μg/kg of ior®LeukoCIM or with 150 μg/kg of Neupogen®. The major adverse treatment-related clinical finding was mild to severe swelling of the hock-joint (tarsal joint) and hind limb, alone or accompanied with lameness which was more prominent in males and which had a similar frequency of occurrence for both ior®LeukoCIM and Neupogen®. All adverse findings were fully reversible. As expected, ior®LeukoCIM and Neupogen® both increased white blood cell and neutrophil levels in rats and to a similar extent for high-dose ior®LeukoCIM and Neupogen®. The pharmacokinetics of filgrastim following dosing with ior®LeukoCIM were well behaved and comparable for high-dose ior®LeukoCIM and Neupogen®. The results of this study imply that ior®LeukoCIM and Neupogen® had similar safety profiles, pharmacodynamic responses, and pharmacokinetic profiles that suggest they are biosimilar.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Albert Licollari, Katherine Riddle, Simon R. Taylor, Nuris Ledon, Gordon T. Bolger,